跳到正文
ECA GMP News·AI 评分47

ECA GMP News:GDP领域近期相关出版物概览(含EMA Annex 15修订概念文件、Swissmedic I-SMI.TI.18e第4.0版及EU Pharma Package进展)

Current Publications Relevant to the GDP Area

AI 导读

EMA就EU GMP指南Annex 15(确认与验证)修订发布概念文件,拟将范围扩展至原料药生产商、强化ICH Q9(R1)质量风险管理整合,并明确运输验证与供应商确认要求,公开征求意见至2026年4月,最终草案预计2026年底出台。

正文 · 原文

In recent weeks, several new publications and position papers have been released that have implications for the GDP area and the management of pharmaceutical supply chains. Below, you will find a concise overview.Revision of Annex 15The European Medicines Agency (EMA) has published a concept paper on the revision of Annex 15 (Qualification and Validation) of the EU GMP Guide.Planned changes include, among others: Extension of the scope to active substance manufacturers Stronger integration of Quality Risk Management (ICH Q9 (R1)) More explicit requirements for transport verification and supplier qualificationA two-month public consultation period is scheduled until April 2026. The final draft is expected by the end of 2026.We have summarised further details in a separate news article.SwissmedicSwissmedic has specified its expectations for companies engaged in international trade in medicinal products with Version 4.0 of Interpretation I-SMI.TI.18e (Legal requirements and mandatory due diligence by Swiss firms wishing to engage in foreign trade with medicinal products or ATMPs from Switzerland, and on supply chain traceability if products are imported for re-export).Key GDP-related aspects include: Import for the purpose of re-export is considered a regular import activity Full application of GDP requirements in import/re-export scenarios Complete supply chain traceability Risk-based supplier qualificationA more detailed summary of the document and the implemented changes is available here.In addition, document I-SMI.RL.02e (Description, harmonisation and steering of the Swiss GMP/GDP inspection system for medicinal products) has been published in a new version; however, no GDP-relevant changes have been introduced.EU Pharma PackageInternal EU coordination indicates that parts of the new EU Pharmaceutical Package will become applicable earlier than publicly communicated. The “Union List of Critical Medicines” is expected to apply from the date of entry into force, with further provisions on security of supply to follow six months later.Further details are available here.

来源:ECA GMP News · gmp-compliance.org